DexCom Inc (DXCM) - Total Liabilities
Based on the latest financial reports, DexCom Inc (DXCM) has total liabilities worth $3.68 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore DexCom Inc equity growth rate to track the company's year-over-year net asset growth rate.
DexCom Inc - Total Liabilities Trend (2003–2025)
This chart illustrates how DexCom Inc's total liabilities have evolved over time, based on quarterly financial data. See DexCom Inc (DXCM) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
DexCom Inc Competitors by Total Liabilities
The table below lists competitors of DexCom Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TechnipFMC PLC
NYSE:FTI
|
USA | $6.72 Billion |
|
Experian plc
F:J2B
|
Germany | €8.14 Billion |
|
Veeva Systems Inc Class A
NYSE:VEEV
|
USA | $1.83 Billion |
|
Givaudan SA
F:GIN1
|
Germany | €7.30 Billion |
|
W. R. Berkley Corp
NYSE:WRB
|
USA | $33.91 Billion |
|
Vestas Wind Systems A/S
CO:VWS
|
Denmark | Dkr22.79 Billion |
|
Edison International
NYSE:EIX
|
USA | $75.59 Billion |
|
PetroChina Company Limited
F:PC6
|
Germany | €1.20 Trillion |
Liability Composition Analysis (2003–2025)
This chart breaks down DexCom Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see DexCom Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DexCom Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DexCom Inc (2003–2025)
The table below shows the annual total liabilities of DexCom Inc from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.59 Billion | -17.98% |
| 2024-12-31 | $4.38 Billion | +4.43% |
| 2023-12-31 | $4.20 Billion | +28.71% |
| 2022-12-31 | $3.26 Billion | +12.75% |
| 2021-12-31 | $2.89 Billion | +17.34% |
| 2020-12-31 | $2.46 Billion | +62.92% |
| 2019-12-31 | $1.51 Billion | +20.73% |
| 2018-12-31 | $1.25 Billion | +158.45% |
| 2017-12-31 | $484.70 Million | +307.31% |
| 2016-12-31 | $119.00 Million | +68.08% |
| 2015-12-31 | $70.80 Million | +59.46% |
| 2014-12-31 | $44.40 Million | +15.63% |
| 2013-12-31 | $38.40 Million | +32.41% |
| 2012-12-31 | $29.00 Million | +81.42% |
| 2011-12-31 | $15.98 Million | -1.15% |
| 2010-12-31 | $16.17 Million | -75.27% |
| 2009-12-31 | $65.39 Million | -21.19% |
| 2008-12-31 | $82.98 Million | +18.30% |
| 2007-12-31 | $70.14 Million | +808.09% |
| 2006-12-31 | $7.72 Million | +5.61% |
| 2005-12-31 | $7.31 Million | -90.70% |
| 2004-12-31 | $78.67 Million | +47.41% |
| 2003-12-31 | $53.37 Million | -- |
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick bloo… Read more